Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout
Big Pharma Executed $6.7bn Deal Without Seeing Phase III Data
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
You may also be interested in...
Abivax Banks €130m To Advance Obefazimod
The French biotech has attracted a raft of new US healthcare specialist backers in one of the biggest raises ever on the Euronext Paris but it will need millions more to complete the late-stage program for obefazimod.
Five Clinical Trial Hits Of 2022
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.
Prometheus Phase II Data For Novel TL1A Inhibitor Impresses On Efficacy
The company plans to move PRA023 forward into Phase III studies based on positive Phase II safety and efficacy data in UC and Crohn's disease, positioning Prometheus in a race with Roivant.